Cancer Discovery - The clinical benefit of PD-1 blockade can be improved by combination with CTLA-4 inhibition but is commensurate with significant irAEs sub-optimally limiting the doses...
Cancer Discovery - The clinical benefit of PD-1 blockade can be improved by combination with CTLA-4 inhibition but is commensurate with significant irAEs sub-optimally limiting the doses...
ICYMI: Design and efficacy of a monovalent #bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1+ activated T cells. @SJDovedi @AstraZeneca #immunotherapy https://t.co/uqcxVPmSLp https://t.co/uqcxVPmSLp